


图 7　TIMP1 高表达样本对博莱霉素和米哚妥林的药物反应

A：博莱霉素；B：米哚妥林

BSR20160107.

[22] WANG J, SUN J, LIU L N, et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy[J]. Nat Med, 2019, 25(4): 656-666. DOI:10.1038/s41591-019-0374-x.

[23] HWANG C F, CHIEN C Y, HUANG S C, et al. Fibulin-3 is associated with tumour progression and a poor prognosis in nasopharyngeal carcinomas and inhibits cell migration and invasion via suppressed AKT activity[J]. J Pathol, 2010, 222(4): 367-379. DOI: 10.1002/path.2776.

[24] HAWTHORN L, STEIN L, VARMA R, et al. TIMP1 and SERPIN-A overexpression and TFF3 and CRABP1 underexpression as biomarkers for papillary thyroid carcinoma[J]. Head Neck, 2004, 26 (12): 1069-1083. DOI:10.1002/hed.20099.

[25] TIAN Z, TAN Y, LIN X, et al. Arsenic trioxide sensitizes pancreatic cancer cells to gemcitabine through downregulation of the TIMP1/PI3K/AKT/mTOR axis[J]. Transl Res, 2023, 255: 66-76. DOI: 10.1016/j.trsl.2022.11.007.

[26] WURTZ S O, SCHROHL A S, MOURIDSEN H, et al. TIMP-1 as a tumor marker in breast cancer--an update[J]. Acta Oncol, 2008, 47 (4): 580-590. DOI:10.1080/02841860802022976.

[27] SHOU Y, LIU Y, XU J, et al. TIMP1 indicates poor prognosis of renal cell carcinoma and accelerates tumorigenesis via EMT signaling pathway[J]. Front Genet, 2022, 13: 648134. DOI: 10.3389/fgene.2022.648134.

[28] MACEDO F C, CUNHA N, PEREIRA T C, et al. A prospective cohort study of TIMP1 as prognostic biomarker in gastric and colon cancer[J]. Chin Clin Oncol, 2022, 11(6): 43. DOI:10.21037/cco-22-69.

（收稿日期：2024-12-30）

读者·作者·编者

敬请关注《中国现代普通外科进展》官方微信平台

《中国现代普通外科进展》官方微信公众号已开通，我们将通过微信平台定期推送本刊优秀文章、活动信息及国内外最新研究成果与进展等。您也可在微信上留言，向我们咨询杂志相关问题并对我们的工作提出意见和建议。《中国现代普通外科进展》微信公众号的开通是我们在移动互联微时代背景下的创新之举，希望能为广大读者与作者带来更多便利。

欢迎扫描二维码，关注《中国现代普通外科进展》官方微信公众号。

《中国现代普通外科进展》编辑部